MILIND JAVLE to Double-Blind Method
This is a "connection" page, showing publications MILIND JAVLE has written about Double-Blind Method.
Connection Strength
0.232
-
Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp). ESMO Open. 2022 02; 7(1):100314.
Score: 0.136
-
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol. 2021 Nov 01; 7(11):1669-1677.
Score: 0.034
-
Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial. J Pain Symptom Manage. 2021 08; 62(2):223-232.e1.
Score: 0.032
-
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 06; 21(6):796-807.
Score: 0.030